MarketPeel
Insider Trading Intelligence
CN

Carole Nuechterlein

ALGS
DIRECTOR · ALIGOS THERAPEUTICS, INC. · CIK 0001665133
FILING MIX · LIFETIME78%/22%
BUYS
14
SELLS
4
TOTAL VALUE
$6.50M
COMPANIES
2
ACTIVE SINCE
Oct 2020
HOLDINGS NOW
17,778
AVG SELL PX
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Carole Nuechterlein, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%+22.03%+1.22%+20.81%+20.81%
14d2+100.00%+20.24%+4.72%+15.52%+15.52%
30d2+100.00%+16.50%+9.04%+7.46%+7.46%
60d2+100.00%+13.89%+13.89%+0.00%+0.00%
90d2+100.00%+10.80%+16.59%-5.79%-5.79%
180d2+100.00%+30.33%+20.54%+9.79%+9.79%
1y2+0.00%-41.23%+40.60%-81.83%-81.83%
2y2+0.00%-36.97%+65.44%-102.41%-102.41%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ALGS · 5,860 shares · as of Jun 25, 2026
02,756,4855,512,9718,269,45611,025,941202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 14 buys / 4 sellsCOVERAGE · 23 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,8605,860Jun 25, 2026Jun 29, 2026View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,8605,860Jun 25, 2025Jun 26, 2025View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,00060,000Jun 27, 2024Jun 28, 2024View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,4114,411Feb 28, 2024Feb 28, 2024View →
ALGS
ALIGOS THERAPEUTICS, INC.
SALE
15,0000Feb 27, 2024Feb 28, 2024View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASE
3,966,800$0.13$495.9K3,966,800Oct 25, 2023Oct 27, 2023View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASE
7,933,601$0.76$6.00M11,025,941Oct 25, 2023Oct 27, 2023View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,00020,000Jul 20, 2023Jul 21, 2023View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 23, 2022Jun 27, 2022View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,91811,918Jun 2, 2022Jun 6, 2022View →
TRDA
ENTRADA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
23,55223,522Oct 28, 2021Nov 1, 2021View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 17, 2021Jun 17, 2021View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASE
662,7992,808,790Oct 20, 2020Oct 20, 2020View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASE
2,145,9912,145,991Oct 20, 2020Oct 20, 2020View →
ALGS
ALIGOS THERAPEUTICS, INC.
SALE
2,145,9910Oct 20, 2020Oct 20, 2020View →
ALGS
ALIGOS THERAPEUTICS, INC.
SALE
283,5500Oct 20, 2020Oct 20, 2020View →
ALGS
ALIGOS THERAPEUTICS, INC.
SALE
662,7990Oct 20, 2020Oct 20, 2020View →
ALGS
ALIGOS THERAPEUTICS, INC.
PURCHASE
283,5503,092,340Oct 20, 2020Oct 20, 2020View →
Other insiders · ALGS
Loading peer insiders…
About this filer
CIK 0001665133
ROLE
Director
PRIMARY
ALGS
COMPANIES
2
ACTIVE SINCE
Oct 2020
MARKETPEEL · /INSIDER/0001665133DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback